RSV INFECTION
RSV (Respiratory Syncytial Virus) is an RNA virus that attaches to the respiratory epithelium, enters the cells, and causes disease. It can lead to a wide spectrum of illnesses, ranging from mild upper respiratory tract infections to severe pneumonia requiring intensive care.
RSV is transmitted through coughing and sneezing and can survive on hard surfaces for several hours. It can remain active on hands for up to 12 hours.
Most hospitalizations due to RSV occur in full-term, otherwise healthy infants. The incubation period ranges from 4 to 6 days, and the contagious period lasts approximately 5 to 6 days.
RSV is the most common cause of lower respiratory tract infections in infants and young children. In children under 1 year of age, it accounts for more than 80% of cases.
By the age of 2, nearly all children (about 90%) have been infected with RSV.
Reinfection is possible; however, the severity of the disease generally decreases with age.
The RSV season typically lasts from October through the end of March.
Household transmission is common.
One-third of deaths due to lower respiratory tract infections in infants under 1 year of age are associated with RSV infection.
How can we protect against RSV?
- Passive immunization (during pregnancy)
- Active immunization (for the infant)
Immunization can be provided with the RSV monoclonal antibody Nirsevimab (Beyfortus), which has been implemented in our country starting from October 2025.
The vaccine approved for use during pregnancy, Abrysvo, can be administered between 32 and 36 weeks of gestation.
